

SHUKRA PHARMACEUTICALS LIMITED

(Formerly known as Relish Pharmaceutical Limited)

R.O.: 1-2 Moon Light 3rd Floor, Opp. Gurukul Drive-In-Road, Memnagar, Ahmedabad 380052 |
Phone: (079)66522247, Fax: 079-27498515 | Email: info@relishpharma.com,
Website: www.relishpharma.com | CIN: L24231GJ1993PLC019079

14th November, 2016

To,
The General Manager-Listing
Corporate Relationship Department
The BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai

Scrip Code: 524632

Dear Sir,

Sub.: Outcome of Board Meeting

With reference to above subject and in compliance with the Listing Agreement, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 14th November, 2016 at 11:00 am and concluded at 03:00 p.m.:-


- 1) Approval of Unaudited Financial Results for the quarter ended on 30th September, 2016.

You are requested to kindly take the same on record.

Thanking You

Yours faithfully,

For Shukra Pharmaceuticals Limited
(Formerly known as Relish Pharmaceuticals Limited)


Dakshesh R. Shah
Managing Director
DIN: 00561666

Encl.: As above

SHUKRA PHARMACEUTICALS LIMITED

(Formerly known as Relish Pharmaceutical Limited)

R.O.: 1-2 Moon Light 3rd Floor, Opp. Gurukul Drive-In-Road, Memnagar, Ahmedabad 380052 |
Phone: (079)66522247, Fax: 079-27498515 | Email: info@relishpharma.com,
Website: www.relishpharma.com | CIN: L24231GJ1993PLC019079

14th November, 2016

To,
The General Manager-Listing
Corporate Relationship Department
The BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai

Scrip Code: 524632

Dear Sir,

Sub: Submission of Financial Result along with Limited Review Report


With reference to above, please find Unaudited Financial Results along with Limited Review Report for the quarter ended on 30th September, 2016 in Compliance with the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to kindly take the same on record.

Thanking You

Yours faithfully,

For Shukra Pharmaceuticals Limited
(Formerly known as Relish Pharmaceuticals Limited)


Dakshesh R. Shah
Managing Director
DIN: 00561666

Encl.: As above

SHUKRA PHARMACEUTICALS LTD
(Formerly known as Relish Pharmaceuticals Limited)

Statement of Standalone Unaudited Results for the Quarter ended 30/09/2016 (In lacs)						
PART I Particulars	3 Months Ended	3 Months Ended	3 Months Ended	6 Months Ended	6 Months Ended	Year to date
	(30-09-2016)	(30-06-2016)	(30-09-2015)	(30-09-2016)	(30-09-2015)	figures for current period ended (31/03/2016)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income from operations						
(a) Net sales/income from operations (Net of excise duty)	91.33	93.60	92.24	184.93	122.33	482.40
(b) Other operating income	0.00	0.00	50.00	0.00	100.00	
Total Income from operations (net)	91.33	93.60	142.24	184.93	222.33	482.40
2 Expenses						
(a) Cost of materials consumed	18.50	24.81	20.46	43.31	68.12	77.30
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1.29	4.91	66.05	3.62	33.13	91.20
(d) Employee benefits expense	25.21	24.30	27.35	49.51	56.48	115.80
(e) Depreciation and amortisation expense	13.15	11.20	15.00	24.35	30.00	44.80
(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	21.37	8.79	4.67	30.16	12.04	79.40
Total expenses	76.94	74.01	133.53	150.95	199.77	408.50
3 Profit / (Loss) from operations before other Income, finance costs and exceptional Items (1-2)	14.39	19.59	8.71	33.98	22.56	73.90
4 Other Income	2.23	0.20	0.38	2.43	0.82	6.80
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	16.62	19.79	9.09	36.41	23.38	80.70
6 Finance costs	0.00		0.00	0.00	0.00	0.10
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	16.62	19.79	9.09	36.41	23.38	80.60
8 Exceptional items	0.00		0.00	0.00	0.00	-40.60
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	16.62	19.79	9.09	36.41	23.38	40.00
10 Tax expense - Provision for taxation	5.50	6.00	0.00	11.50	0.00	23.10
11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)	11.12	13.79	9.09	24.91	23.38	16.90
12 Extraordinary items	0.00		0.00	0.00	0.00	0.00
13 Net Profit / (Loss) for the period (11 + 12)	11.12	13.79	9.09	24.91	23.38	16.90
14 Share of profit / (loss) of associates*	0.00		0.00	0.00	0.00	0.00
15 Minority interest *	0.00		0.00	0.00	0.00	0.00
16 Net Profit / (Loss) after taxes, minority Interest and share of profit / (loss) of associates (13 + 14 + 15) *	11.12	13.79	9.09	24.91	23.38	16.90
17 Paid-up equity share capital (Face Value of the Share shall be indicated)	156.57	156.57	156.57	156.57	156.57	156.57
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00
19.i Earnings per share (before extraordinary Items) (of Rs.10/- each) (not annualised):						
(a) Basic	0.07	0.09	0.06	0.16	0.15	0.11
(b) Diluted	0.07	0.09	0.05	0.16	0.15	0.11
19.ii Earnings per share (after extraordinary Items) (of Rs. 10/- each) (not annualised):						
(a) Basic	0.07	0.09	0.06	0.16	0.15	0.11
(b) Diluted	0.07	0.09	0.06	0.16	0.15	0.11

- Notes: 1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 14th November 2016
2. The Company has only single Reportable Business Segment in terms of requirements of Accounting Standard 17.
3. Previous quarter's figures have been re-grouped / re-arranged wherever necessary.

For Shukra Pharmaceuticals Limited
(Formerly known as Relish Pharmaceuticals Limited)


Place : Ahmedabad
Date : 14/11/2016

Dakshesh R. Shah
Managing Director
DIN: 00561666

SHUKRA PHARMACEUTICALS LTD
(Formerly known as Relish Pharmaceuticals Limited)


PART II						
Quarter Ended 30/09/2016						
Particulars	3 Months Ended (30-09-2016)	3 Months Ended (30-06-2016)	3 Months Ended (30-09-2015)	6 Months Ended (30-09-2016)	6 Months Ended (30-09-2015)	Year to date figures for current period ended (31/03/2016)
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
- Number of shares	769770	769770	769770	769770	769770	769770
- Percentage of shareholding	49.17%	49.17%	49.17%	49.17%	49.17%	49.17%
2	Promoters and Promoter Group Shareholding **					
a) Pledged/Encumbered						
- Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non-encumbered						
- Number of shares	795905	795905	795905	795905	795905	795905
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	50.83%	50.83%	50.83%	50.83%	50.83%	50.83%

Particulars	3 months ended 30/09/2016
B	
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	0
Received during the quarter	0
Disposed of during the quarter	0
Remaining unresolved at the end of the quarter	0



SHUKRA PHARMACEUTICALS LTD
(Formerly known as Relish Pharmaceuticals Limited)

STATEMENT OF ASSETS AND LIABILITIES		STANDALONE	
		As at current period ended 30-09-2016 (Unaudited)	As at current year end 31-3-2016 (Audited)
		A EQUITY AND LIABILITIES	
1 SHAREHOLDERS FUNDS			
(a) Share Capital	156.57	156.57	
(b) Reserves and surplus	1275.69	1250.78	
(c) Money received against share warrant			
SHAREHOLDERS FUNDS	1432.26	1407.35	
2 SHARE APPLICATION MONEY PENDING ALLOTMENT			
3 NON - CURRENT LIABILITIES			
(a) Long-term borrowing	0	0	
(b) Deferred tax liabilities (net)	244.14	244.14	
(c) Other long-term liabilities		0	
(d) long-term provisions		0	
NON - CURRENT LIABILITIES	244.1	244.1	
4 CURRENT LIABILITIES			
(a) Short-term borrowing	3.6	3.6	
(b) Trade payables	20.51	25.55	
(c) Other current liabilities	0	0	
(d) Short-term provision	24.68	0	
CURRENT LIABILITIES	48.79	29.15	
TOTAL EQUITY AND LIABILITIES	1725.19	1681	
B ASSETS			
1 NON - CURRENT ASSETS			
(a) Fixed assets	1137.05	1135.6	
(b) Non-current investments	4.15	4.15	
(c) Deferred tax assets (net)		0	
(d) long-term loans and advances		0	
(e) Other non-current assets	8.27	9.27	
NON - CURRENT ASSETS	1149.47	1149.02	
2 CURRENT ASSETS			
(a) Current investments	0	0	
(b) Inventories	40.04	43.65	
(c) Trade receivables	58.93	86.14	
(d) Cash and cash equivalents	148.58	174.41	
(e) Short-term loans and advances	287.65	179.51	
(f) Other current assets	40.52	47.89	
CURRENT ASSETS	575.72	531.6	
TOTAL ASSETS	1725.19	1681	





To
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED

REVIEW REPORT FOR THE QUARTER ENDED ON 30th SEPTEMBER .2016


Ref: SHUKRA PHARMACEUTICALS LIMITED


We have reviewed the accompanying statement of unaudited financial results of Shukra Pharmaceuticals Limited for the period ended on 30th SEPTEMBER, 2016 except for the disclosures regarding (Public Shareholding and (Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors and Committee of the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, engagement to Review Financial Statement issued by the Institute of Chartered Accountant of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in accounting standards and interim financial reporting, specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement".

For B.J.Trivedi & Associates
ICAI Firm Registration Number: 111042W
Chartered Accountants


Bharat Trivedi
Proprietor
Membership No- 039595



Place: Ahmedabad
Date: 12/11/2016